糖尿病の微小血管合併症：グローバル医薬品市場予測・分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 13
1.1 List of Tables 20
1.2 List of Figures 24
2 Introduction 27
2.1 Catalyst 27
2.2 Related Reports 28
2.3 Upcoming Related Reports 28
3 Disease Overview 29
3.1 Etiology and Pathophysiology 31
3.1.1 Diabetic Nephropathy 31
3.1.2 Diabetic Retinopathy 33
3.1.3 Diabetic Neuropathy 34
3.2 Prognosis 35
3.3 Quality of Life 36
3.4 Symptoms 37
4 Epidemiology 38
4.1 Diabetic Nephropathy 38
4.1.1 Disease Background 38
4.1.2 Risk Factors and Comorbidities 39
4.1.3 Global Trends 40
4.1.4 Forecast Methodology 43
4.1.5 Forecast Assumptions and Methods, Diagnosed Prevalent Cases of Diabetes 47
4.1.6 Forecast Assumptions and Methods — Diabetic Nephropathy 51
4.1.7 Epidemiology Forecast for Diabetic Nephropathy (2012-2022) 53
4.1.8 Discussion 59
4.2 Diabetic Retinopathy 61
4.2.1 Disease Background 61
4.2.2 Risk Factors and Comorbidities 63
4.2.3 Global Trends 63
4.2.4 Forecast Methodology 68
4.2.5 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 74
4.2.6 Forecast Assumptions and Methods — Diabetic Retinopathy 78
4.2.7 Epidemiology Forecast for Diabetic Retinopathy (2012-2022) 80
4.2.8 Discussion 87
4.3 Diabetic Neuropathy 89
4.3.1 Disease Background 89
4.3.2 Risk Factors and Comorbidities 90
4.3.3 Global Trends 90
4.3.4 Forecast Methodology 93
4.3.5 Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes 98
4.3.6 Forecast Assumptions and Methods — Diabetic Neuropathy 102
4.3.7 Epidemiology Forecast for Diabetic Neuropathy (2012-2022) 103
4.3.8 Discussion 111
4.3.9 Limitations of the Analysis 112
4.3.10 Strengths of the Analysis 113
5 Disease Management 114
5.1 Treatment Overview 114
5.1.1 Diagnosis and Referrals 114
5.1.2 Screening 116
5.1.3 Treatment Guidelines 117
5.2 US 124
5.2.1 Diagnosis 124
5.2.2 Clinical Practice 126
5.3 France 128
5.3.1 Diagnosis 128
5.3.2 Clinical Practice 129
5.4 Germany 131
5.4.1 Diagnosis 131
5.4.2 Clinical Practice 132
5.5 Italy 133
5.5.1 Diagnosis 133
5.5.2 Clinical Practice 134
5.6 Spain 136
5.6.1 Diagnosis 136
5.6.2 Clinical Practice 137
5.7 UK 138
5.7.1 Diagnosis 138
5.7.2 Clinical Practice 141
5.8 Japan 144
5.8.1 Diagnosis 144
5.8.2 Clinical Practice 146
6 Competitive Assessment 148
6.1 Overview 148
6.2 Strategic Competitor Assessment 149
6.3 Diabetic Nephropathy: Product Profiles – Major Classes and Brands 153
6.3.1 Angiotensin-Converting Enzyme (ACE) Inhibitors 153
6.3.2 Angiotensin Receptor Blockers 157
6.4 Diabetic Retinopathy: Product Profiles – Major Classes and Brands 161
6.4.1 Lucentis (ranibizumab) 161
6.4.2 Avastin (bevacizumab) 167
6.4.3 Corticosteroid Intravitreal Implants 172
6.5 Diabetic Neuropathy: Product Profiles – Major Classes and Brands 177
6.5.1 Tricyclic Antidepressants 177
6.5.2 Serotonin-Norepinephrine Reuptake Inhibitors – Cymbalta (duloxetine) and Effexor (venlafaxine) 180
6.5.3 Anticonvulsants – Neurontin (gabapentin) and Lyrica (pregabalin) 185
6.5.4 Opioids 191
6.5.5 Epalrestat 194
7 Opportunity and Unmet Need 198
7.1 Overview 198
7.2 Unmet Needs 199
7.2.1 Unified Treatment for the Microvascular Complications of Diabetes 199
7.2.2 Optimization of Personalized Therapy in the Microvascular Complications of Diabetes 199
7.2.3 Treatment for Diabetic Nephropathy that Would Prevent ESRD 201
7.2.4 Cardio- and Renoprotective Therapy for Diabetic Nephropathy 202
7.2.5 Efficient Therapy for Retinopathy 203
7.2.6 Convenient Administration in Diabetic Retinopathy Treatment 203
7.2.7 Treatment for Diabetic Neuropathy 204
7.3 Unmet Needs Gap Analysis 205
7.4 Opportunity: Therapy for the Underlying Cause of the Microvascular Complications of Diabetes 207
7.5 Opportunity: Patient-Tailored Therapy for the Microvascular Complications of Diabetes 207
7.6 Opportunity: Efficacious Therapy for Diabetic Nephropathy 208
7.7 Opportunity: Topical Treatment for Diabetic Retinopathy 208
7.8 Opportunity: Treatment for Diabetic Neuropathy 209
8 Pipeline Assessment 210
8.1 Overview 210
8.2 Clinical Trial Mapping 212
8.2.1 Clinical Trials by Country 212
8.3 Clinical Trials by Phase and Trial Status 213
8.4 Promising Drugs in Clinical Development 215
8.4.1 Eylea (aflibercept) 217
8.4.2 Optina (danazol) 223
8.4.3 Atrasentan Hydrochloride 229
8.4.4 Ranirestat 234
9 Current and Future Players 239
9.1 Overview 239
9.2 Trends in Corporate Strategy 241
9.3 Company Profiles 244
9.3.1 Roche 244
9.3.2 Novartis 246
9.3.3 Regeneron 248
9.3.4 Bayer 250
9.3.5 Eli Lilly 251
9.3.6 Pfizer 254
9.3.7 AbbVie 256
10 Market Outlook 259
10.1 Global Markets 259
10.1.1 Forecast 259
10.1.2 Drivers and Barriers – Global Issues 263
10.2 US 266
10.2.1 Forecast 266
10.2.2 Key Events 271
10.2.3 Drivers and Barriers 271
10.3 France 274
10.3.1 Forecast 274
10.3.2 Key Events 279
10.3.3 Drivers and Barriers 279
10.4 Germany 282
10.4.1 Forecast 282
10.4.2 Key Events 287
10.4.3 Drivers and Barriers 287
10.5 Italy 290
10.5.1 Forecast 290
10.5.2 Key Events 295
10.5.3 Drivers and Barriers 295
10.6 Spain 298
10.6.1 Forecast 298
10.6.2 Key Events 303
10.6.3 Drivers and Barriers 303
10.7 UK 306
10.7.1 Forecast 306
10.7.2 Key Events 311
10.7.3 Drivers and Barriers 311
10.8 Japan 314
10.8.1 Forecast 314
10.8.2 Key Events 320
10.8.3 Drivers and Barriers 320
11 Appendix 323
11.1 Bibliography 323
11.2 Abbreviations 347
11.3 Methodology 354
11.4 Forecasting Methodology 354
11.4.1 Diagnosed Patients 354
11.4.2 Percent Drug-Treated Patients 355
11.4.3 Drugs Included in Each Therapeutic Class 355
11.4.4 Launch and Patent Expiry Dates 355
11.4.5 General Pricing Assumptions 356
11.4.6 Individual Drug Assumptions 357
11.4.7 Generic Erosion 361
11.4.8 Pricing of Pipeline Agents 361
11.5 Physicians and Specialists Included in this Study 362
11.6 About the Authors 364
11.6.1 Analyst II – CVMD 364
11.6.2 Therapy Director – CVMD and Infectious Disease 364
11.6.3 Senior Epidemiologist 365
11.6.4 Global Head of Healthcare 365
11.7 About GlobalData 366
11.8 Disclaimer 366